BOSTON, April 10 /PRNewswire/ -- Perceptive Informatics, Inc., the technology subsidiary of PAREXEL International Corporation , today announced that board certified neurologist and leading central nervous system (CNS) expert Dr. James Paskavitz has joined the Company as a Medical Director. Dr Paskavitz will provide leadership and oversee all CNS initiatives within the Perceptive Informatics Medical Imaging Division.
“I am pleased to welcome Dr. Paskavitz to our team. We believe his scientific expertise and leadership will further leverage Perceptive’s advanced medical imaging techniques in CNS clinical trials to enable clients to detect early evidence of efficacy, accelerate go/no-go decisions, and decrease the time and cost associated with clinical development,” said Todd Joron, Corporate Vice President and General Manager of Perceptive Informatics.
Dr. Paskavitz is a behavioral neurologist and brings to PAREXEL significant neuro-imaging expertise. He has extensive experience with movement disorders, multiple sclerosis, and neuro-rehabilitation. Dr. Paskavitz was the first to develop human brain mapping at the University of Colorado and University of Massachusetts. His research, presented internationally, included studying the physiology of disease states, which incorporated CNS indication areas such as Alzheimer’s disease, multiple sclerosis and stroke. Previously, Dr. Paskavitz led one of the largest dementia practices in the northeastern United States. Dr. Paskavitz holds an MD from the University of Massachusetts Medical School. He completed a residency in neurology and fellowship in behavioral neurology at the University of Colorado. Dr. Paskavitz is a former faculty member at UMass Memorial Healthcare. He is a member of several neurology associations, and is Board Certified by American Board of Psychiatry and Neurology.
Dr. Paskavitz is part of a team of therapeutic and medical imaging experts in the Perceptive Informatics Medical Imaging Division that provides sponsors with a range of capabilities in the application of imaging techniques, used from early development through peri-approval studies. The Perceptive Informatics Medical Imaging Division has expertise in multiple therapeutic areas, as well as significant experience in the use of novel modalities such as FDG-PET (fluorodeoxyglucose-positron emission tomography) and DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging).
About PAREXEL
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS) and integration services. Headquartered near Boston, Massachusetts, PAREXEL operates in 51 locations throughout 39 countries around the world, and has approximately 5,360 employees. For more information about PAREXEL International visit http://www.PAREXEL.com.
About Perceptive Informatics
Perceptive Informatics, Inc. combines clinical knowledge, quality and regulatory experience with advanced technology to decrease time to market, risk and cost associated with clinical trials. Perceptive’s portfolio includes Medical Imaging, Clinical Trial Management Systems (CTMS), Interactive Voice Response Systems (IVRS & IWRS), and Integration Services as well as web-based portal solutions, tracking tools, electronic diaries and investigator database solutions. Perceptive offers medical imaging services to rapidly and objectively assess the safety and efficacy of new drugs, biologics and medical devices in clinical trials. The IMPACT(TM) solution is Perceptive’s market-leading CTMS product with 25,000 users worldwide, and INITIATOR(TM) is a trial management product targeted to the needs of Phase I units. For more information about Perceptive Informatics, visit http://www.perceptive.com.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the amendment or interpretation of Financial Accounting Standards Board Statement No. 123 (revised 2004), Share-Based Payment (“Statement 123R”), which could change the Company’s current assessment of the effects of the adoption of Statement 123R on the acceleration of equity grants, the assumptions inherent in equity pricing models under Statement 123R and the final results of the closing of the Company’s books for future financial periods; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry; competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the period ended December 31, 2005 as filed with the SEC on February 9, 2006, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.
Media Contact: Jennifer Baird, Director of Public Relations PAREXEL International Tel: +1.781.434.4409 Email: Jennifer.Baird@PAREXEL.com
Perceptive Informatics, Inc.
CONTACT: Jennifer Baird, Director of Public Relations of PAREXELInternational, +1-781-434-4409, Jennifer.Baird@PAREXEL.com
